A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

BACKGROUND: In the ongoing COVID-19 pandemic, advanced age is a risk factor for a severe clinical course of SARS-CoV-2 infection. Thus, older people may benefit in particular from booster doses with potent vaccines and research should focus on optimal vaccination schedules. In addition to each indiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuhann, Julia M., Stemler, Jannik, Carcas, Antonio, Frías-Iniesta, Jesús, Bethe, Ullrich, Heringer, Sarah, Tischmann, Lea, Zarrouk, Marouan, Cüppers, Arnd, König, Franz, Posch, Martin, Cornely, Oliver A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547672/
https://www.ncbi.nlm.nih.gov/pubmed/36209129
http://dx.doi.org/10.1186/s13063-022-06791-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547672/
https://www.ncbi.nlm.nih.gov/pubmed/36209129
http://dx.doi.org/10.1186/s13063-022-06791-y

Ejemplares similares